课题基金 / 基金详情

EASTERN COOPERATIVE ONCOLOGY GROUP

EASTERN COOPERATIVE ONCOLOGY GROUP
东方肿瘤合作组
批准号:
2099890
负责人:
CARLA I FALKSON
金额:
$5.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-08 至 1997-04-30

项目摘要

项目成果

CARLA I FALKSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述:比勒陀利亚大学自1972年以来一直是经社理事会的成员, 正在请求提供支持,以促进继续参加经社理事会。AS 作为经社理事会的成员,该机构正试图改善 癌症患者的生命质量和持续时间通过发展和 科学评估对所有人最有效的治疗方案 癌症的类型和分期。本计划的具体目标是:(1) 在所有ECOG中保持完全可评估的患者的高应收率 治疗和非治疗方案;(2)维持和完善 有效的数据管理计划;(3)继续为 开发创新的治疗方案并继续保持领导地位 在经社理事会的科学计划中;(4)发表经社理事会的成果 研究;(5)继续介绍收集到的科学信息 经社理事会在国家和国际会议上;和(6)作出贡献 到ECOG和NCI关于肝细胞癌,食道癌, 和间皮瘤,该机构拥有独特的资源。 来自比勒陀利亚大学的调查人员担任主席或曾担任 在不同的疾病领域进行了几项ECOG研究。其中包括恶性 黑色素瘤、乳腺癌、原发性肝癌、间皮瘤和 食道癌。
英文摘要
DESCRIPTION: The University of Pretoria, a member of ECOG since 1972, is requesting support to facilitate continued participation in ECOG. As a member of ECOG, this institution is attempting to improve both the quality and duration of cancer patients' lives by developing and scientifically evaluating the most effective treatment programs for all types and stages of cancer. The specific aims of this program are: (1) to maintain a high accrual rate of fully evaluable patients on all ECOG therapeutic and non-therapeutic protocols; (2) to maintain and refine an effective data management program; (3) to continue contribution to the development of innovative treatment protocols and continue leadership in the scientific programs of ECOG; (4) to publish results of ECOG studies; (5) to continue to present the scientific information gathered by ECOG at national and international meetings; and (6) to contribute to ECOG and NCI programs on hepatocellular carcinoma, esophagus cancer, and mesothelioma where this institution has unique resources. Investigators from the University of Pretoria chair or have chaired several ECOG studies in various disease areas. These include malignant melanoma, breast cancer, primary liver cancer, mesothelioma, and esophagus cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
E2104 TRIAL OF AVASTIN DD ADRIAMYCIN AND CYTOXAN FOLLOWED BY TAXOL IN LYMPH NODE
UAB 0461 BEVACIZUMAB TO REVERSE ACQUIRED ESTROGEN INDEPENDENCE IN BREAST CANCER
Phase III chemoprevention trial with selenium in NSCLC
High dose interferon vs observation in st. 3-4 melanoma
海外基金